ClinicalTrials.gg
Drug

Zanubrutinib clinical trials

Also written BGB-3111 and Brukinsa.

studies test it
146
open now
81
in phase 3
12
first study started
2014

How each study uses zanubrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the zanubrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Nov 2019 · BRUKINSA · NDA 213217 (FDA, Drugs@FDA)
European Union
22 Nov 2021 · Brukinsa · EMEA/H/C/004978 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Zanubrutinib
106
BTK-InhB
8
Zanubrutinib Oral Product
2
Zanubrutinib Oral Capsule
2
BTK inihibitor
2

Brand

Brukinsa
44

Development codes

BGB-3111
47

Studies by the year they started

145 studies that test it; most in 2024 (26); 1 more planned to start later

Studies that test zanubrutinib, by start year
YearStudies
20141
20164
20177
20184
20194
202015
20219
202222
202317
202426
202519
202617

Who runs them

Industry 34 · Other 112

BeiGene (28) · Institute of Hematology & Blood Diseases Hospital, China (10) · Ruijin Hospital (10) · BeOne Medicines (6) · Peking University People's Hospital (5) · The First Affiliated Hospital of Soochow University (5) · Peking Union Medical College Hospital (5) · The First Affiliated Hospital with Nanjing Medical University (5)

Often tested with

Tested in the same studies.

Rituximab (30) · Lenalidomide (17) · Obinutuzumab (14) · Bendamustine (9) · Sonrotoclax (7) · Polatuzumab vedotin (6) · Venetoclax (5) · Methotrexate (5)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Zanubrutinib is the comparator. A study of two new drugs counts under both.

  • 1Pirtobrutinib · Loxo Oncology, Inc. · next primary completion Nov 2027
  • 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 29, 2 in phase 3

Studies that test zanubrutinib, phase 3 first.

Studies

Open first, then newest update. How each study uses zanubrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 146

See all 146 studies that test zanubrutinib →

Given beside what is tested · 33 — zanubrutinib is usual care or a partner of the new treatment

Showing 20 of 33.

As the comparator · 4 — what is tested is compared with zanubrutinib

Codes

What other systems call zanubrutinib · ClinicalTrials.gg INT001030

  • MeSH (NLM) C000629551zanubrutinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) AG9MHG098ZZANUBRUTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2262435One source FDA
  • Wikidata Q75192022zanubrutinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C141428ZanubrutinibOne source FDA
  • DrugBank DB15035One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.